Annual report for FY 2024-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Ltd, a Telangana-based pharmaceutical company listed on BSE (Scrip Code: 538965), has filed its Annual Report for FY 2024-25 and announced its 30th Annual General Meeting on Tuesday, 30th September 2025 at 9:30 AM, to be held via video conferencing. The register of members will be closed from 24th September to 30th September 2025, with the e-voting cut-off date fixed as 23rd September 2025. Key resolutions include re-appointment of promoter directors Mr. S. Nagi Reddy (CMD), Mr. S. Koni Reddy and Mr. S. Manoj Kumar Reddy (Whole-time Directors) for 5-year terms, appointment of Mr. Satyam Reddy Gopidi as a new Independent Director, and approval of related party transactions for FY 2025-26 worth up to Rs. 15 crore each with four promoter-linked entities — Proton Remedies, Cortex Laboratories, Seelam Laboratories, and Continental Pellets Pharma. The company also proposes appointing M/s. PSK & Associates as Secretarial Auditors for a 5-year term (FY 2025-30) and ratifying the cost auditor's remuneration at Rs. 1 lakh.
This is a routine annual compliance filing with standard governance resolutions. Shareholders should particularly review the related party transaction proposals (Rs. 15 crore limit each with four promoter-connected firms) as these involve promoter group dealings. No fresh financial numbers, dividends, or material business updates were disclosed in the notice excerpt beyond a general reference to 'steady operational performance.'